Corrigendum.
Kalincik T, Jokubaitis V, Spelman T, et al. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Mult Scler. Epub ahead of print 31 August 2017. DOI: 10.1177/1352458517728812 On page 5 of this article there was a typographical error in the initial Online First version. The fourth line of the first paragraph that read 'The probability of disability accumulation was similar in the two matched cohorts (HR: 0.41 (95% CI: 0.87-1.47), p = 0.37)' should have read 'The probability of disability accumulation was similar in the two matched cohorts (HR: 0.61 (95% CI: 0.20-1.82), p=0.37)'. The incorrect values were also repeated in Figure 2b. Both the sentence and the figure have now been corrected online. The authors apologise for any inconvenience.